Unlock instant, AI-driven research and patent intelligence for your innovation.

Anthracycline encapsulated with polysaccharide for use in treatment of tumours

An anthracycline and polysaccharide technology, applied in the field of new drug forms of polysaccharide-coated anthracycline

Pending Publication Date: 2021-01-01
NANOVELOS
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

High cardiotoxicity poses a particularly high risk when anthracyclines are taken in their current form because free radicals produced by anthracyclines cause peroxidation of the sarcoplasmic reticulum of the heart, leading to calcium 2+ mediated myocardial necrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anthracycline encapsulated with polysaccharide for use in treatment of tumours
  • Anthracycline encapsulated with polysaccharide for use in treatment of tumours
  • Anthracycline encapsulated with polysaccharide for use in treatment of tumours

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045]Production of Polysaccharide Coated Anthracycline

[0046](a) Preparation of dextran-coated epirubicin (NPs_EPI)

[0047]According to the method of preparing nanoparticles from polysaccharides as described in patent PL221251 (see Examples 2 and 4 for details), dextran and dodecylamine hydrochloride with a molecular weight of 70kDa (degree of oxidation of 5-15%) are used, Preparation of dextran coated epirubicin. The degree of substitution of the aldehyde group produced by the winding agent dodecylamine in the dextran is 10-20%. The degree of substitution of aldehyde groups produced by epirubicin in dextran is 4-10%. The other generated aldehyde groups were replaced by alanine. Using NanoSight LM 10 (405nm laser) in an aqueous solution, the average particle size of the prepared nanoparticles is between 80 and 140nm (figure 1 A). The determined epirubicin content in the dry matter of the nanoparticles is 3.0-5%. The obtained nanoparticles were freeze-dried and stored in a sealed conta...

Embodiment 2

[0056]Cytotoxicity determination of polysaccharide-encapsulated anthracycline on cell lines (drug-bound nanoparticles)

[0057]The subject of this study is to determine the cytotoxicity of anthracyclines encapsulated with polysaccharides EPI, DAU, DOX, and IDA on cell lines. A quantitative method based on colorimetric technology (MTT) was used to assess toxicity [see item 203]. In this test, the amber dehydrogenase present in the cell converts soluble tetrazolium salt (3-4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide into reduced form. The reaction produces water-insoluble purple crystalline formazan. The number of crystals formed depends on the activity of the enzyme, so it is directly proportional to the number of living cells in the sample. Spectrophotometric measurement requires the use of organic solvents to dissolve the obtained crystals (isopropanol). The change in color intensity was measured by spectrophotometry at a wavelength of 570nm. The dilutions (9) of various...

Embodiment 3

[0087]Determination of the anti-tumor effect of polysaccharide coated anthracycline

[0088]A) Determination of the maximum tolerated dose (MTD) of dextran-coated epirubicin (NPs-EPI)

[0089]Using the acute oral toxicity-up and down method according to OECD method No. 425, the MTD measurement method was used to perform acute treatment on the polysaccharide-coated anthracycline in the form of dextran-coated epirubicin (NPs-EPI) produced in Example 1. For toxicity evaluation, the route of administration of the test material was changed.

[0090]Intravenous administration (iv; injection into the tail vein) is determined by the administration of epirubicin in the currently used form, that is, epirubicin hydrochloride (EPI) to patients, if the anti-tumor efficacy of NPs-EPI is If confirmed, NPs-EPI will be administered.

[0091]The acute toxicity assessment method used is an alternative method recommended by the OECD (OECD Method No. 425), which takes into account the purpose of improving animal we...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle sizeaaaaaaaaaa
sizeaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention relates to a new form of a drug in the form of anthracycline encapsulated with a polysaccharide selected from epirubicin, daunorubicin, doxorubicin, idarubicin, especially encapsulated with dextran, for use in the treatment of specific tumours.

Description

Technical field[0001]The present invention relates to a new drug form of anthracycline encapsulated by polysaccharides for the treatment of specific tumors. The polysaccharides are selected from epirubicin, daunorubicin, doxorubicin, idarubicin, especially dextran sugar. This new form of drug administration can increase the relative dosage of chemotherapeutic agents, improve their targeting to the desired effect site, while ensuring lower toxicity to the body, thereby improving the use of polysaccharide-encapsulated anthracyclines for anti-tumor ( The effectiveness of anti-cancer) drug therapy.[0002]technical background[0003]Anthracyclines are anti-cancer antibiotics and are widely used as low-dose chemotherapy drugs for various tumors, especially leukemia, metastatic breast cancer, ovarian cancer, colon cancer and rectal cancer. Anthracycline interferes with the functions of basic cellular processes, including DNA reading and replication and cellular protein synthesis. These drugs ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/00A61K9/16A61K47/69
CPCA61K9/0019A61K9/16A61K47/6939A61K9/5161A61K31/704A61P35/00A61K9/4866A61K47/36
Inventor 伊加·瓦西克亚当·基西亚克托马斯·凯驰亚历山大·库里科夫斯卡·达拉克彼得·皮特扎克艾格尼丝·索比奇卡维奥莱塔·科尼奇乔安娜·皮特拉斯保罗·泽柔保罗·祖克贾斯汀纳·马科斯卡金达·阿达姆斯卡尼古拉斯·克罗姆斯基
Owner NANOVELOS